TickerFacts.

China SXT Pharmaceuticals, Inc. (SXTC): Long-Term Debt

Annual figures by period end, from SEC filings.

$807.2K
As of 2025-03-31
+85.7%
5-year compound annual growth
2019-03-31: $41.7K2020-03-31: $36.5K2021-03-31: $6.3K2024-03-31: $631.5K2025-03-31: $807.2K$807.2K
2019-03-31 Long-Term Debt (USD) 2025-03-31
Period endedLong-Term DebtChange YoYSource filing
2025-03-31$807.2K+27.8%2025-07-31, Balance as of period end
2024-03-31$631.5Kn/a2024-08-13, Balance as of period end
No annual figure between 2021-03-31 and 2024-03-31.
2021-03-31$6.3K-82.8%2023-05-19, Balance as of period end
2020-03-31$36.5K-12.5%2021-08-13, Balance as of period end
2019-03-31$41.7Kn/a2020-07-31, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
China SXT Pharmaceuticals, Inc. (SXTC)2025-03-31$807.2K+27.8%
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$150.0K0.0%
Northwest Biotherapeutics Inc (NWBO)2025-12-31$60.04M-4.2%
NRX Pharmaceuticals, Inc. (NRXP)2023-12-31$9.16M-13.0%
Rani Therapeutics Holdings, Inc. (RANI)2024-12-31$25.00M-16.7%
Bio Essence Corp (BIOE)2025-12-31$57.5K+1.8%
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$109.59M+6.9%
Yarrow Bioscience, Inc. (YARW)2025-12-31$0n/a
Scienture Holdings, Inc. (SCNX)2024-12-31$2.90Mn/a

Compare SXTC, SXTP, NWBO, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗